(4R,4aR,7R,7aR,12bS)-3-(cyclopropylmethyl)-7-(methylamino)-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-9-ol | 152657-08-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: (4R,4aR,7R,7aR,12bS)-3-(cyclopropylmethyl)-7-(methylamino)-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-9-ol
• CAS: 152657-08-4
• 化学式: C₂₁H₂₈N₂O₂
• 分子量: 340.466
• InChiKey: SGGHBQOCLYFPNC-FSWWCVKVSA-N

物化性质

• 沸点：
  505.3±50.0 °C(predicted)
• 密度：
  1.30±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  44.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4R,4aR,7R,7aR,12bS)-3-(cyclopropylmethyl)-7-(methylamino)-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-9-ol 、 (E)-3-(furan-3-yl)acryloyl chloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (2E)-N-[(5R,6R)-17-(cyclopropylmethyl)-4,5-epoxy-3-hydroxymorphinan-6-yl]-3-(furan-3-yl)-N-methylprop-2-enamide
  参考文献：
  名称：

  Essential structure of opioid κ receptor agonist nalfurafine for binding to the κ receptor 2: Synthesis of decahydro(iminoethano)phenanthrene derivatives and their pharmacologies

  摘要：

  To clarify the essential structures of an opioid kappa receptor selective agonist, nalfurafine, for binding to the kappa receptor, we designed and synthesized some nalfurafine derivatives and the decahydro(iminoethano)phenanthrene derivatives with a cyclohexene moiety as a surrogate for the phenol ring. In addition to the 6-amide side chain and the 17-nitrogen substituted by a cyclopropylmethyl group, the 4,5-epoxy ring, phenolic hydroxy group, and angular hydroxy group played important roles in eliciting the binding properties of nalfurafine but these three moieties were not indispensable for binding to the kappa receptor. Moreover, the phenol ring was also not essential for the binding to the kappa receptor, and the cyclohexene moiety would play an important role in fixing the conformation of decahydro(iminoethano) phenanthrene derivatives to effectively raise the amide side chain, rendering a conformation that resembled the active one of nalfurafine. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.122
• 作为产物：
  描述：

  17-(cyclopropylmethyl)-4,5α-epoxy-6-oxo-morphinan 在 palladium on activated charcoal 、 氢气 、 对甲苯磺酸 、 苯甲酸 作用下， 以 甲醇 、 苯 为溶剂， 生成 (4R,4aR,7R,7aR,12bS)-3-(cyclopropylmethyl)-7-(methylamino)-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-9-ol
  参考文献：
  名称：

  Essential structure of opioid κ receptor agonist nalfurafine for binding to the κ receptor 2: Synthesis of decahydro(iminoethano)phenanthrene derivatives and their pharmacologies

  摘要：

  To clarify the essential structures of an opioid kappa receptor selective agonist, nalfurafine, for binding to the kappa receptor, we designed and synthesized some nalfurafine derivatives and the decahydro(iminoethano)phenanthrene derivatives with a cyclohexene moiety as a surrogate for the phenol ring. In addition to the 6-amide side chain and the 17-nitrogen substituted by a cyclopropylmethyl group, the 4,5-epoxy ring, phenolic hydroxy group, and angular hydroxy group played important roles in eliciting the binding properties of nalfurafine but these three moieties were not indispensable for binding to the kappa receptor. Moreover, the phenol ring was also not essential for the binding to the kappa receptor, and the cyclohexene moiety would play an important role in fixing the conformation of decahydro(iminoethano) phenanthrene derivatives to effectively raise the amide side chain, rendering a conformation that resembled the active one of nalfurafine. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.122

文献信息

• MORPHINAN DERIVATIVE AND MEDICINAL USE
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP0577847A1

  公开（公告）日：1994-01-12

  A morphinan derivative represented by general formula (1) or a pharmacologically acceptable acid addition salt thereof, an analgesic and diuretic containing the same as the active ingredient, and a process for producing the same The invention compound has potent analgesic and diuretic activities as a highly selective κ-opioid agonist, thus being useful as an analgesic and diuretic.

  一种由通式（1）代表的吗啡南衍生物或其药理上可接受的酸加成盐，一种含有吗啡南衍生物作为活性成分的镇痛剂和利尿剂，以及生产吗啡南衍生物的工艺。 本发明化合物作为一种高选择性κ-阿片激动剂，具有强效的镇痛和利尿活性，因此可用作镇痛剂和利尿剂。
• Morphinan derivative and its pharmaceutical applications
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP0846694A1

  公开（公告）日：1998-06-10

  A morphinan derivative represented by the general formula (I) or its pharmacologically acceptable acid addition salt:    wherein R5 is a specified cyclic ring, B is C1-14 alkylene and A is -XC(=Y)-, -XC(=y)z-, -X-, -XSO2- or -OC(OR4)(R4)- (where X is NCH3, NH, S or O, but is other than NCH3 when R6 and R7 together form -O-, each A, Y and Z, independently, is NR4, S or O and R4 is H, C1-5 alkyl or C6-12 aryl) have analgesic activity.

  由通式（I）或其药理学上可接受的酸加成盐代表的吗啡南衍生物： 其中 R5 为特定的环，B 为 C1-14 亚烷基，A 为 -XC(=Y)-、-XC(=y)z-、-X-、-XSO2- 或 -OC(OR4)(R4)-（其中 X 为 NCH3、NH、S 或 O，但当 R6 和 R7 共同形成 -O- 时为 NCH3 以外，每个 A、Y 和 Z 独立地为 NR4、S 或 O，R4 为 H、C1-5 烷基或 C6-12 芳基）具有镇痛活性。
• Design, synthesis, and structure–activity relationship of novel opioid κ-agonists
  作者：Koji Kawai、Jun Hayakawa、Toru Miyamoto、Yoshifumi Imamura、Shinichi Yamane、Hisanori Wakita、Hideaki Fujii、Kuniaki Kawamura、Hirotoshi Matsuura、Naoki Izumimoto、Ryosuke Kobayashi、Takashi Endo、Hiroshi Nagase

  DOI：10.1016/j.bmc.2008.09.011

  日期：2008.10

  By focusing on 4,5-epoxymorphinan, a traditional opioid skeleton but a new structure in the opioid kappa-agonist research field, and by rationally applying the 'message-address concept' and 'accessory site hypothesis,' we discovered a new chemical class opioid kappa- gonist, TRK-820 (1). Its development as an antipruritus is now in the final stage. Here, the full scope of its design, synthesis, and structure-activity relationship are described. (C) 2008 Elsevier Ltd. All rights reserved.
• US6177438B1
  申请人：——

  公开号：US6177438B1

  公开（公告）日：2001-01-23
• US6277859B1
  申请人：——

  公开号：US6277859B1

  公开（公告）日：2001-08-21